What the appeals court indicated yesterday.... was that...the simple step that all generic Vascepa companies should take to avoid infringing... was to simply indicate on their label that..."icosapentethyl is biosimilar to Vascepa, but only for use in very high triglycideremia"...That easy solution would solve the infringement problem...Unfortunately, it would be a solution that infringing generic companies would be very hesitant to take, since it would severely impact their profits from Vascepa.
Market Data 
Markets 
AI
